Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members are generally comfortable with use of the GLP-1 receptor agonist in the first-line setting, suggesting that a second-line treatment restriction in diabetes could be lifted.
You may also be interested in...
Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
US FDA does not raise any major concerns about study’s design or results to support cardiovascular risk reduction claim for Novo Nordisk’s GLP-1 agonist liraglutide ahead of advisory committee, but agency gives close scrutiny to non-CV safety events of interest.
FDA Panel To Weigh Relevance Of Liraglutide’s Diabetes Experience In Obesity
Agency will ask external advisors Sept. 11 how the GLP-1 agonist’s safety in type 2 diabetes, approved as Victoza in 2010, informs the safety profile in obesity, where Novo Nordisk is seeking a higher dose and a different name.
FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.